pixantrone has been researched along with Brill-Symmers Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glavey, S; Morris, J; Murphy, P; O'Reilly, M; Quinn, J; Sargent, J | 1 |
| Allievi, C; Bernareggi, A; Cabanillas, F; Fayad, L; Laffranchi, B; Levine, AM; Lim, ST; Modiano, M; Tulpule, A | 1 |
1 trial(s) available for pixantrone and Brill-Symmers Disease
| Article | Year |
|---|---|
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
1 other study(ies) available for pixantrone and Brill-Symmers Disease
| Article | Year |
|---|---|
Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
Topics: Humans; Isoquinolines; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen | 2022 |